GTS 21

Drug Profile

GTS 21

Alternative Names: DMXB-A; DMXB-A sustained release; DMXB-A-SR

Latest Information Update: 15 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiho Pharmaceutical; University of Florida
  • Developer CoMentis
  • Class Benzylidene compounds; Neuroprotectants; Nootropics; Pyridines; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder
  • Discontinued Alzheimer's disease; Cognition disorders

Most Recent Events

  • 28 Apr 2015 University of Florida plans a phase II trial for Smoking withdrawal in USA (NCT02432066)
  • 04 Apr 2014 University of Colorado at Denver plans a phase I trial for Autistic disorder in USA (NCT02111551)
  • 07 Apr 2008 GTS 21 is still in Phase-I/II trials for Attention deficit hyperactivity disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top